Peptides News and Research

RSS

AD risk genes impact Aβ toxicity in neurons

In a development that sheds new light on the pathology of Alzheimer's disease (AD), a team of Whitehead Institute scientists has identified connections between genetic risk factors for the disease and the effects of a peptide toxic to nerve cells in the brains of AD patients.

28 Oct 2011

Yo-yo dieting can affect appetite hormones for up to a year

A new study suggests that the ‘yo-yo’ effect that dieters experience of shedding pounds and gaining them back may be due to the persistence of hormones that drive the urge to eat even a year after weight loss.

27 Oct 2011

DNA synbodies, a new class of affinity reagents, gets major NIH boost

An ongoing Arizona State University effort to develop a revolutionary class of reagents that holds great promise for the future of medicine has received a major boost with a three-year, $4 million award from the National Institutes of Health.

24 Oct 2011

Six young investigators receive IOF's Young Investigator Award for bone research

Six young investigators from the Middle East have been awarded prestigious grants in recognition of their top ranked research abstracts presented at the IOF Regionals - 1st Middle-East & Africa Osteoporosis Meeting.

22 Oct 2011

NIH awards Scripps Research scientist for research into Type I diabetes

A scientist at The Scripps Research Institute has been awarded $4.2 million from the National Institutes of Health in a program to advance what the agency calls "bold and creative research" into Type I diabetes.

14 Oct 2011

Researchers control itch without dulling morphine's pain-killing effects

Itching is one of the most prevalent side effects of powerful, pain-killing drugs like morphine, oxycodone and other opioids. The opiate-associated itch is so common that even women who get epidurals for labor pain often complain of itching. For many years, scientists have scratched their own heads about why drugs that so effectively suppress pain also induce itch.

14 Oct 2011

WuXi PharmaTech announces acquisition of Abgent

WuXi PharmaTech Inc., a leading pharmaceutical, biotechnology and medical device research and development services company with operations in China and the United States, today announced the acquisition of Abgent, Inc., a provider of biological research reagent products and services based in Suzhou, China, and San Diego, California.

14 Oct 2011

Simmons Center to evaluate CGEN-25009 for treatment of idiopathic pulmonary fibrosis

Compugen Ltd. and the Pulmonary Fibrosis Foundation announced today that the Pulmonary Fibrosis Foundation will provide a grant to scientists at the University of Pittsburgh Dorothy P. and Richard P.

13 Oct 2011

Gantenerumab appears to reduce brain amyloid levels in patients with AD

Although it is a small study and more clinical trials are needed, treatment with the medication gantenerumab appeared to result in a reduction in brain amyloid levels in patients with Alzheimer disease, according to a report published Online First by Archives of Neurology, one of the JAMA/Archives journals.

11 Oct 2011

FDA clears Cardium's new Excellagen topical gel for diabetic foot ulcers

Cardium Therapeutics announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market and sell the Company's new Excellagen professional-use, sterile, syringe-based advanced wound care product for the management of diabetic foot ulcers and other dermal wounds.

11 Oct 2011

Cardium's Excellagen topical gel for diabetic foot ulcers receives FDA 510(k) clearance

Cardium Therapeutics announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market and sell the Company's new Excellagen™ professional-use, sterile, syringe-based advanced wound care product for the management of diabetic foot ulcers and other dermal wounds.

10 Oct 2011

Neutrophils inhibit restenosis in patients with atherosclerosis after stent implantation

A research team led by LMU's Professor Christian Weber has now shown that a specific cell type called neutrophils, and molecules that they secrete, inhibit this life-threatening complication - which is observed in up to one-third of all stent implantations.

7 Oct 2011

New NIH grant to continue exploration of Fusobacterium nucleatum-associated Beta-Defensin Inducer

Research from Case Western Reserve University School of Dental Medicine to study an isolated agent from common oral bacteria may hold the answer as to how human beta defensins (HBDs)-nature's way of keeping oral microbes from entering the body and wreaking havoc with our health-can be used to create new treatments to block bacteria from entering through the epithelial linings on and in the body.

4 Oct 2011

Researchers apply new approach to take a close look at amyloid plaque formation

Researchers at the University of Toronto Scarborough (UTSC) and Osaka University applied a new approach to take a close look at amyloid plaque formation, a process that plays important roles in Alzheimer's disease.

4 Oct 2011

Adaptimmune announces new board appointments as clinical programmes get underway

Adaptimmune, the T cell therapy company pioneering enhanced T cell receptor-driven T cells for the treatment of cancer and infectious disease, announces two new Board appointments with immediate effect. Dr Jonathan Knowles joins the Board as a non-executive director and Dr Helen Tayton-Martin, Adaptimmune’s Chief Operating Officer, becomes an executive director.

3 Oct 2011

La Jolla Institute scientist identifies previously unknown T cell interaction

Most of the time, the immune system is the body's protector, warding off invading viruses and bacteria before they can lead to infection and disease. But in autoimmune diseases, the immune system does an about face, turning on the body and attacking normal cells.

3 Oct 2011

Amorfix achieves 85% specificity and sensitivity with EP-AD CSF Diagnostic Test for AD

Amorfix Life Sciences, a product development company focused on diagnostics and therapeutics for misfolded protein diseases, today announced it has achieved 85 percent specificity and sensitivity with its EP-AD CSF Diagnostic Test.

1 Oct 2011

Free radical peroyxnitrite linked to failure of cytotoxic T-cells to eliminate tumors

Researchers at the Moffitt Cancer Center in Tampa, Fla., and colleagues have found that tumor cell resistance to a specific cancer immunotherapy designed to kill cancer cells can be blamed on a mechanism that involves the production of a free radical peroxynitrite (PNT) that causes resistance to therapeutic cancer-killing cells.

30 Sep 2011

Galectin posts new corporate video on galectin-inhibiting therapeutics to treat fibrosis and cancer

Galectin Therapeutics Inc. today announced that it posted a new corporate presentation video to its website, www.galectintherapeutics.com, that highlights the Company's leadership position in developing galectin-inhibiting therapeutics to treat fibrosis and cancer.

30 Sep 2011

New process makes linear peptides circular

Peptides and proteins have long been an attractive class of drug candidates because of their natural involvement in cellular processes and fewer potential side effects. Dr. Andrei Yudin, Professor, Department of Chemistry, University of Toronto, has developed a new and effective process that makes linear peptides circular, which allows these molecules, called macrocycles, to enter cells more effectively and increase their stability compared to linear peptides.

29 Sep 2011

Peptides News and Research

AD risk genes impact Aβ toxicity in neurons

Yo-yo dieting can affect appetite hormones for up to a year

DNA synbodies, a new class of affinity reagents, gets major NIH boost

Six young investigators receive IOF's Young Investigator Award for bone research

NIH awards Scripps Research scientist for research into Type I diabetes

Researchers control itch without dulling morphine's pain-killing effects

WuXi PharmaTech announces acquisition of Abgent

Simmons Center to evaluate CGEN-25009 for treatment of idiopathic pulmonary fibrosis

Gantenerumab appears to reduce brain amyloid levels in patients with AD

FDA clears Cardium's new Excellagen topical gel for diabetic foot ulcers

Cardium's Excellagen topical gel for diabetic foot ulcers receives FDA 510(k) clearance

Neutrophils inhibit restenosis in patients with atherosclerosis after stent implantation

New NIH grant to continue exploration of Fusobacterium nucleatum-associated Beta-Defensin Inducer

Researchers apply new approach to take a close look at amyloid plaque formation

Adaptimmune announces new board appointments as clinical programmes get underway

La Jolla Institute scientist identifies previously unknown T cell interaction

Amorfix achieves 85% specificity and sensitivity with EP-AD CSF Diagnostic Test for AD

Free radical peroyxnitrite linked to failure of cytotoxic T-cells to eliminate tumors

Galectin posts new corporate video on galectin-inhibiting therapeutics to treat fibrosis and cancer

New process makes linear peptides circular

Editorial Focus eBook - Peptides and Oligonucleotides (2nd edition) eBook

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News